Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Barinthus Biotherapeutics plc (BRNS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: BRNS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -77.32% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 42.36M USD | Price to earnings Ratio - | 1Y Target Price 4.5 |
Price to earnings Ratio - | 1Y Target Price 4.5 | ||
Volume (30-day avg) 17692 | Beta -0.8 | 52 Weeks Range 0.80 - 4.16 | Updated Date 03/30/2025 |
52 Weeks Range 0.80 - 4.16 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.55 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-03-18 | When Before Market | Estimate -0.37 | Actual -0.2021 |
Profitability
Profit Margin - | Operating Margin (TTM) -304.98% |
Management Effectiveness
Return on Assets (TTM) -15.22% | Return on Equity (TTM) -38.58% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -56298636 | Price to Sales(TTM) 2.83 |
Enterprise Value -56298636 | Price to Sales(TTM) 2.83 | ||
Enterprise Value to Revenue 0.62 | Enterprise Value to EBITDA -6.67 | Shares Outstanding 40339400 | Shares Floating 25979781 |
Shares Outstanding 40339400 | Shares Floating 25979781 | ||
Percent Insiders 13.54 | Percent Institutions 46.17 |
Analyst Ratings
Rating 4.67 | Target Price 7.25 | Buy 1 | Strong Buy 2 |
Buy 1 | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Barinthus Biotherapeutics plc
Company Overview
History and Background
Barinthus Biotherapeutics plc, previously known as VaxEquity, was formed in 2020 as a joint venture between Vaccitech and Oxford Science Enterprises. It focuses on developing novel T cell immunotherapeutics and prophylactic vaccines using heterologous prime-boost regimens.
Core Business Areas
- Therapeutic Vaccines: Development of vaccines to prevent infectious diseases. They use a prime-boost approach to stimulate a strong T-cell response.
- T Cell Immunotherapeutics: Developing immunotherapies to treat chronic infections and cancers.
Leadership and Structure
The leadership team includes experienced professionals in biotechnology and pharmaceuticals. The organizational structure is designed to support research, development, and clinical trials.
Top Products and Market Share
Key Offerings
- VTP-300: A therapeutic vaccine for chronic Hepatitis B virus (HBV) infection. Currently in Phase 2 clinical trials. Market share is yet to be determined. Competitors include companies developing HBV therapeutics and vaccines, such as Gilead Sciences (GILD), Vir Biotechnology (VIR), and Assembly Biosciences (ASMB).
- VTP-1000: A vaccine for the treatment of Celiac disease. Currently in Phase 1. Market share is yet to be determined. Competitors include companies developing celiac disease treatments, such as Innovate Biopharmaceuticals (INNT) and Amgen (AMGN) who are exploring various therapeutic approaches.
Market Dynamics
Industry Overview
The biotechnology industry is experiencing rapid growth, driven by advancements in genomics, immunology, and drug delivery. There's a growing demand for innovative therapies and vaccines.
Positioning
Barinthus Biotherapeutics plc is positioned as an innovative company with a focus on T cell immunotherapy. Their prime-boost approach offers a potential competitive advantage in stimulating robust immune responses.
Total Addressable Market (TAM)
The TAM for therapeutic vaccines and immunotherapies is substantial, estimated at billions of dollars. Barinthus is positioned to capture a share of this market with its unique approach, contingent upon successful clinical trial outcomes.
Upturn SWOT Analysis
Strengths
- Novel T cell immunotherapy platform
- Strong scientific foundation
- Experienced leadership team
- Partnership with Vaccitech and Oxford Science Enterprises
Weaknesses
- Early stage clinical development
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on clinical trial success
Opportunities
- Expanding pipeline with new therapeutic targets
- Partnerships with pharmaceutical companies
- Regulatory approvals for lead candidates
- Growing demand for immunotherapies
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- GILD
- VIR
- BMY
- MRK
Competitive Landscape
Barinthus Biotherapeutics plc is competing with larger, more established pharmaceutical companies. Its competitive advantage lies in its innovative T cell immunotherapy platform and prime-boost approach. Disadvantages include limited financial resources and early stage development.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is defined by preclinical and early-stage clinical development activities.
Future Projections: Future growth depends on successful clinical trial outcomes, regulatory approvals, and commercialization efforts.
Recent Initiatives: Recent initiatives include advancing lead candidates through clinical trials and securing partnerships for funding and development.
Summary
Barinthus Biotherapeutics shows promise with its innovative T cell immunotherapy platform, yet it is early stage. The company depends heavily on clinical trial successes and securing funding. Its competitive landscape is dominated by industry giants, making partnerships crucial for sustained growth. Investors should monitor clinical progress and financial stability.
Similar Companies
- GILD
- VIR
- BNTX
- MRNA
- MRK
- BMY
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- ClinicalTrials.gov
- Analyst Reports (where available)
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor. Market share data is an estimate and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Barinthus Biotherapeutics plc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-04-30 | CEO & Director Mr. William J. Enright MBA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 105 | Website https://www.barinthusbio.com |
Full time employees 105 | Website https://www.barinthusbio.com | ||
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.